4.4 Article

Poor asthma control and exposure to traffic pollutants and obesity in older adults

Journal

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
Volume 108, Issue 6, Pages 423-+

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.anai.2012.04.009

Keywords

-

Funding

  1. National Institute of Environmental Health Services [P30-ES006096, ES11170]
  2. US Public Health Service [UL1 RR026314]
  3. National Center for Research Resources
  4. National Center for Advancing Translational Sciences, National Institutes of Health [8KL2 TR000078-04]

Ask authors/readers for more resources

Background: Environmental and host predictors of asthma control in older asthmatic patients (>65 years old) are poorly understood. Objective: To examine the effects of residential exposure to traffic exhaust and other environmental and host predictors on asthma control in older adults. Methods: One hundred four asthmatic patients 65 years of age or older from allergy and pulmonary clinics in greater Cincinnati, Ohio, completed the validated Asthma Control Questionnaire (ACQ), pulmonary function testing, and skin prick testing to 10 common aeroallergens. Patients had a physician's diagnosis of asthma, had significant reversibility in forced expiratory volume in 1 second or a positive methacholine challenge test result, and did not have chronic obstructive pulmonary disease. The mean daily residential exposure to elemental carbon attributable to traffic (ECAT) was estimated using a land-use regression model. Regression models were used to evaluate associations among independent variables, ACQ scores, and the number of asthma exacerbations, defined as acute worsening of asthma symptoms requiring prednisone use, in the past year. Results: In the adjusted model, mean daily residential exposure to ECAT greater than 0.39 mu g/m(3) was significantly associated with poorer asthma control based on ACQ scores (adjusted beta = 2.85; 95% confidence interval [CI], 0.58-5.12; P = .02). High ECAT levels were also significantly associated with increased risk of asthma exacerbations (adjusted odds ratio, 3.24; 95% CI, 1.01-10.37; P = .05). A significant association was found between higher body mass index and worse ACQ scores (adjusted beta = 1.15; 95% CI, 0.53-1.76; P < .001). Atopic patients (skin prick test positive) had significantly better ACQ scores than nonatopic patients (adjusted beta = -0.39; 95% CI, -0.67 to -0.11; P < .01). Conclusion: Higher mean daily residential exposure to traffic exhaust, obesity, and nonatopic status are associated with poorer asthma control among older asthmatic patients. (C) 2012 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Allergy

Needs assessment: knowledge of self-management of asthma for children with co-morbid physical and intellectual disabilities: brief report

Laura A. Nabors, Jonathan A. Bernstein, Tonya A. Winders, Mary Hart, Filiberto Toledano-Toledano

Summary: The study surveyed professionals and parents to assess their knowledge and perceptions about education for self-management of asthma for children with physical and intellectual disabilities, as well as the need for education on asthma and coronavirus for children with IDs. Results showed that teachers had lower knowledge regarding educating children with IDs about asthma management and coronavirus, highlighting the importance of educating teachers on asthma triggers and involving children in self-care.

JOURNAL OF ASTHMA (2022)

Article Allergy

The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Torsten Zuberbier, Amir Hamzah Abdul Latiff, Mohamed Abuzakouk, Susan Aquilina, Riccardo Asero, Diane Baker, Barbara Ballmer-Weber, Christine Bangert, Moshe Ben-Shoshan, Jonathan A. Bernstein, Carsten Bindslev-Jensen, Knut Brockow, Zenon Brzoza, Herberto Jose Chong Neto, Martin K. Church, Paulo R. Criado, Inna V. Danilycheva, Corinna Dressler, Luis Felipe Ensina, Luz Fonacier, Matthew Gaskins, Krisztian Gaspar, Asli Gelincik, Ana Gimenez-Arnau, Kiran Godse, Margarida Goncalo, Clive Grattan, Martine Grosber, Eckard Hamelmann, Jacques Hebert, Michihiro Hide, Allen Kaplan, Alexander Kapp, Aharon Kessel, Emek Kocaturk, Kanokvalai Kulthanan, Desiree Larenas-Linnemann, Antti Lauerma, Tabi A. Leslie, Markus Magerl, Michael Makris, Raisa Y. Meshkova, Martin Metz, Daniel Micallef, Charlotte G. Mortz, Alexander Nast, Hanneke Oude-Elberink, Ruby Pawankar, Paolo D. Pigatto, Hector Ratti Sisa, Maria Isabel Rojo Gutierrez, Sarbjit S. Saini, Peter Schmid-Grendelmeier, Bulent E. Sekerel, Frank Siebenhaar, Hanna Siiskonen, Angele Soria, Petra Staubach-Renz, Luca Stingeni, Gordon Sussman, Andrea Szegedi, Simon Francis Thomsen, Zahava Vadasz, Christian Vestergaard, Bettina Wedi, Zuotao Zhao, Marcus Maurer

Summary: The updated international guideline for urticaria was developed jointly by multiple international organizations, with participants from 50 countries and international societies, aiming to provide expert guidance on diagnostic and therapeutic approaches for different subtypes of urticaria.

ALLERGY (2022)

Review Allergy

Review of evidence supporting the use of nasal corticosteroid irrigation for chronic rhinosinusitis

Jonathan A. Bernstein, Andrew A. White, Joseph K. Han, David M. Lang, David Elkayam, Fuad M. Baroody

Summary: This study aimed to analyze published reports on the efficacy and safety of corticosteroid irrigation (CSI) in chronic rhinosinusitis (CRS) with nasal polyps and evaluate its clinical implications. CSI is commonly used for the treatment of CRS, but it is not approved by the FDA.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)

Article Allergy

The One Health approach for allergic diseases and asthma

Marek Jutel, Giselle S. Mosnaim, Jonathan A. Bernstein, Stefano del Giacco, David A. Khan, Kari C. Nadeau, Isabella Pali-Schoell, Maria J. Torres, Magdalena Zemelka-Wiacek, Ioana Agache

Summary: The One Health approach is a collaborative and interdisciplinary strategy that focuses on the interconnections between human, animal, and environmental health. It can advance the management of allergic diseases and asthma by addressing their complex and multifactorial nature. The impacts of allergens, infectious agents, and irritants on allergic diseases and asthma are influenced by environmental health intertwined with animal health. A coordinated response across sectors such as public health, veterinary medicine, and environmental science is needed, along with activities like monitoring and surveillance, targeted interventions, and research on underlying mechanisms.

ALLERGY (2023)

Article Immunology

A focused report on progestogen hypersensitivity

Diti H. H. Patel, Lauren M. M. Fine, Jonathan A. A. Bernstein

Summary: Progestogen Hypersensitivity (PH) is characterized by recurrent cutaneous eruptions and systemic symptoms, caused by increased sensitivity to progestogens. The prevalence of PH is expected to increase due to the widespread use of oral contraceptives and hormonal treatments. A better understanding of the underlying mechanisms and the development of accurate diagnostic tests are needed for improved recognition and management of the condition.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2023)

Review Allergy

Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach

Matthew Greenhawt, Timothy E. Dribin, Elissa M. Abrams, Marcus Shaker, Derek K. Chu, David B. K. Golden, Cem Akin, Akterini Anagnostou, Faisal Almuhizi, Waleed Alqurashi, Peter Arkwright, James L. Baldwin, Aleena Banerji, Philippe Begin, Moshe Ben-Shoshan, Jonathan Bernstein, Theresa A. Bingemann, Carsten Bindslev-Jensen, Kim Blumenthal, Aideen Byrne, Julia Cahill, Scott Cameron, Dianne Campbell, Ronna Campbell, Michael Cavender, Edmond S. Chan, Sharon Chinthrajah, Pasquale Comberiati, Jacqueline J. Eastman, Anne K. Ellis, David M. Fleischer, Adam Fox, Pamela A. Frischmeyer-Guerrerio, Remi Gagnon, Lene H. Garvey, Mitchell H. Grayson, Ghislaine Annie Clarisse Isabwe, Nicholas Hartog, David Hendron, Caroline C. Horner, Johnathan O'B Hourihane, Edward Iglesia, Manstein Kan, Blanka Kaplan, Constance H. Katelaris, Harold Kim, John M. Kelso, David A. Khan, David Lang, Dennis Ledford, Michael Levin, Jay A. Lieberman, Richard Loh, Douglas P. Mack, Bruce Mazer, Ketan Mody, Gisele Mosnaim, Daniel Munblit, S. Shahzad Mustafa, Anil Nanda, Richard Nathan, John Oppenheimer, Iris M. Otani, Miguel Park, Ruby Pawankar, Kirsten P. Perrett, Jonny Peter, Elizabeth J. Phillips, Matthieu Picard, Mitchell Pitlick, Allison Ramsey, Trine Holm Rasmussen, Melinda M. Rathkopf, Hari Reddy, Kara Robertson, Pablo Rodriguez del Rio, Stephen Sample, Ajay Sheshadri, Javed Sheik, Sayantani B. Sindher, Jonathan M. Spergel, Cosby A. Stone, David Stukus, Mimi L. K. Tang, James M. Tracy, Paul J. Turner, Timothy K. Vander Leek, Dana V. Wallace, Julie Wang, Susan Wasserman, David Weldon, Anna R. Wolfson, Margitta Worm, Mona-Rita Yacoub

Summary: This guidance provides updates on immediate allergic reactions following COVID-19 vaccines, including recommendations for revaccinating individuals with first-dose allergic reactions and conducting allergy testing. The recommendations were formed by an international panel of experts and are based on recent meta-analyses and diagnostic accuracy studies.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Review Allergy

Scoping review: multiple stakeholders and child asthma management interventions

Samuel Adabla, Laura A. Nabors, Olutosin Sanyaolu, Afolakemi Olaniyan, Jonathan A. Bernstein

Summary: This study reviewed research on interventions aimed at improving asthma management among children by educating parents and other professionals. Stakeholders developed programs that resulted in improvements in asthma symptoms, knowledge of asthma management, perceptions of health care, and decreased emergency health care visits. Successful interventions involved education about asthma management, providing medications, and partnerships with school staff, healthcare teams, and community members.

JOURNAL OF ASTHMA (2023)

Review Allergy

Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Wasuchon Chaichan, Chidchanok Ruengorn, Kednapa Thavorn, Brian Hutton, Jacek C. Szepietowski, Jonathan A. Bernstein, Mati Chuamanochan, Surapon Nochaiwong

Summary: A systematic review and network meta-analysis were conducted to compare the safety profiles of different second-generation H1-antihistamines in patients with chronic urticaria. The study found variations in safety profiles, with mizolastine, emedastine, and cetirizine associated with unfavorable safety profiles.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Medicine, General & Internal

Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria

Jonathan A. Bernstein, Ana Gimenez-Arnau, Marcus Maurer, Petra Staubach, Nathalie Barbier, Eva Hua, Thomas Severin, Pedro A. Laires, Maria-Magdalena Balp

Summary: This study investigated the association between urticaria activity and health-related quality of life. The results showed that chronic spontaneous urticaria significantly impacted the patients' HRQoL. Patients with complete response to treatment had no impairments on health-related quality of life and improved work capacities compared to those with minimal disease activity.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Medicine, Research & Experimental

Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review

Jonathan A. Bernstein, Jean-Pierre Llanos, Gillian Hunter, Neil Martin, Christopher S. Ambrose

Summary: This study describes the reduction of annualized asthma exacerbation rate (AAER) from randomized controlled trials (RCTs) in patients with allergic severe asthma. The study found that the efficacy of biologics varied considerably overall and by baseline blood eosinophil count (BEC), with tezepelumab consistently demonstrating the greatest reduction in AAER across all subgroups.

ADVANCES IN THERAPY (2023)

Article Allergy

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy

P. J. de Kam, S. Zielen, J. A. Bernstein, U. Berger, M. Berger, M. Cuevas, D. Cypcar, A. Fuhr-Horst, W. A. Greisner, M. Jandl, S. Lassmann, M. Worm, J. Matz, E. Sher, C. Smith, G. C. Steven, R. Moesges, M. H. Shamji, L. DuBuske, F. Borghese, K. Oluwayi, T. Zwingers, M. Seybold, O. Armfield, M. D. Heath, S. J. Hewings, M. F. Kramer, M. A. Skinner

Summary: The study evaluated the efficacy and safety of a modified grass allergen subcutaneous immunotherapy for grass-pollen allergic rhinitis/rhinoconjunctivitis. The results showed clinically relevant and statistically significant improvements in symptom and medication scores, as well as a good safety profile.

ALLERGY (2023)

Editorial Material Allergy

Recall urticaria with infusion of agalsidase beta

Raagini Suresh Yedidi, Jonathan A. Bernstein

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)

Review Allergy

An updated review of pediatric autoimmune neuropsychiatric disorders associated with Streptococcus/pediatric acute-onset neuropsychiatric syndrome, also known as idiopathic autoimmune encephalitis: What the allergist should know

Hannah Hardin, Wenhai Shao, Jonathan A. Bernstein

Summary: This article provides an updated review on the diagnosis, management, and treatment of pediatric autoimmune neuropsychiatric disorder associated with streptococcus and pediatric autoimmune neuropsychiatric syndrome, also known as idiopathic autoimmune encephalitis (IAE). The study outlines current knowledge on IAE pathophysiology, clinical manifestations, and epidemiology, as well as diagnostic recommendations and treatment guidelines. The article emphasizes the need for interdisciplinary collaboration and further research to improve the recognition and acceptance of this condition.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)

Article Allergy

A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema

Remy S. Petersen, Laura Bordone, Marc A. Riedl, Raffi Tachdjian, Timothy J. Craig, William R. Lumry, Michael E. Manning, Jonathan A. Bernstein, Jason Raasch, Bruce L. Zuraw, Yiwen Deng, Kenneth B. Newman, Veronica J. Alexander, Cindy Lui, Eugene Schneider, Danny M. Cohn

Summary: The 2-year interim results of this phase 2 open-label extension study of donidalorsen in patients with HAE demonstrated no new safety signals. Donidalorsen was well tolerated with durable efficacy, resulting in a 96% reduction in HAE attacks.

ALLERGY (2023)

No Data Available